TD Cowen initiated coverage of Sionna Therapeutics (SION) with a Buy rating. Sionna’s pipeline of cystic fibrosis therapies directly target NBD1, which was previously thought to be “undruggable,” and in vitro and early clinical data suggest the company’s NBD1 drug candidates may improve or normalize CFTR function in combonations therapies. SION-719 and SION-451 are in Phase 1 trials with data due in the first half of this year and a Phase 2a proof of concept trial will start in the second half with data due in 2026, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SION:
- Goldman Sachs starts Sionna Therapeutics with Early-Stage Biotech designation
- Innovative Approach to Cystic Fibrosis Treatment: Sionna Therapeutics’ Pioneering Pipeline Earns Buy Rating
- Sionna Therapeutics initiated with a Buy at Stifel
- Sionna Therapeutics initiated with a Buy at Guggenheim
- Sionna Therapeutics: Promising NBD1 Stabilizers Poised to Challenge Vertex in the $11 Billion CF Market
Questions or Comments about the article? Write to editor@tipranks.com